Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
Andrew R. Allen, BM, BCh, MA, MRCP, PhD
Advertisement
Articles by Andrew R. Allen, BM, BCh, MA, MRCP, PhD
Advertisement
Latest Updated Articles
Selecting Patients for Treatment with CO-1686Published: September 3rd 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
